| Assessment Status | Rapid Review Complete |
| HTA ID | 22048 |
| Drug | Melatonin |
| Brand | Slenyto® |
| Indication | For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. |
| Assessment Process | |
| Rapid review commissioned | 05/07/2022 |
| Rapid review completed | 09/08/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of prolonged release melatonin (Slenyto®) compared with the current standard of care. |
| Full HTA commissioned by the HSE | 31/08/2022 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.